Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of CCFM1025 in preparation of foods or drugs for alleviating autism and absorbing PCBs

A CCFM1025, autism technology, applied in food or medicine, can solve problems such as neuron function damage, achieve the effect of alleviating social barriers, alleviating muscle rigidity and posture and gait disorders, and improving cognitive ability

Inactive Publication Date: 2020-01-10
JIANGNAN UNIV
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Continuous activity and proliferation of glial cells (astrocytes and microglia) with morphological changes, the release of various pro-inflammatory mediators (cytokines and chemokines) to coordinate immune responses and regulate neuronal function and connectivity, while this response can be neuroprotective (i.e., help repair damaged tissue), chronic dysregulation of CNS cytokines can lead to disruption of neuronal function through their roles in cognition and synaptic regulation, These cytokines include IL-6 and TNF-α, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of CCFM1025 in preparation of foods or drugs for alleviating autism and absorbing PCBs
  • Application of CCFM1025 in preparation of foods or drugs for alleviating autism and absorbing PCBs
  • Application of CCFM1025 in preparation of foods or drugs for alleviating autism and absorbing PCBs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042]Example 1: Bifidobacterium breve CCFM1025 has good tolerance to simulated gastrointestinal fluid

[0043] Inoculate cryopreserved Bifidobacterium breve CCFM1025 in mMRS medium (MRS medium + 0.05% cysteine ​​hydrochloride), culture anaerobically at 37°C for 48 hours, and subculture in mMRS medium for 2-3 After the second time, take 1 mL of the culture solution of Bifidobacterium breve CCFM1025, mix it with 9.0 mL of pH 2.5 artificial simulated gastric juice (containing 1% pepsin, mMRS medium at pH = 2.5), and culture it anaerobically at 37°C. Samples were taken at 0h, 0.5h, 1h, and 2h, and the mMRS agar medium was poured to culture the plate colonies, and the number of viable bacteria was determined and the survival rate was calculated.

[0044] The survival rate is the ratio of the logarithmic value of the number of viable bacteria at the time of sampling to the logarithmic value of the number of viable bacteria at the 0th hour in the culture solution, expressed in %. T...

Embodiment 2

[0049] Embodiment 2: Bifidobacterium breve CCFM1025 has no toxic and side effects to wistar rats

[0050] Bifidobacterium breve CCFM1025 cells were resuspended in 10% skim milk to make a concentration of 3.0×10 8 CFU / mL bacterial suspension. Six male wistar autistic rats with a body weight of about 200 g were taken. After one week of adaptation to the environment, the bacterial suspension of this concentration was administered orally once a day, observed for one week, and the death and body weight were recorded.

[0051] The results of these tests are listed in Table 3. These results indicate that feeding concentrations of 3.0×10 8 CFU / mL of Bifidobacterium breve CCFM1025 had no significant impact on rats, no significant change in body weight, and no death. The appearance of the rats showed no obvious pathological symptoms.

[0052] Table 3 Changes in body weight and death of mice

[0053]

[0054]

[0055] Note: -: Rats did not die

Embodiment 3

[0056] Example 3: Bifidobacterium breve CCFM1025 can significantly improve the autonomous exploration ability of autistic rats

[0057] (1) Breeding of young mice with autism

[0058] Healthy male and female wistar rats were bred and adapted to the environment for 1 week. They were caged together at 5:00 p.m. at a ratio of 2:1, and the vaginal plug was observed at 8:00 the next morning. If no vaginal plug was observed, a vaginal smear was performed. On the first day of pregnancy, the female mice were housed in separate cages after conception, and randomly divided into model group and control group. On the 12.5th day after pregnancy, intraperitoneal injection of sodium valproate (VPA) 600mg / kg (normal saline made into 250mg / mL solution) was given as the model group; Weaning.

[0059]

[0060] (2) Experimental grouping of autistic rats

[0061] Divided into control group, model group and intervention group.

[0062]

[0063] (3) Open field test of autistic rats

[006...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of CCFM1025 in preparation of foods or drugs for alleviating autism and absorbing PCBs. Bifidobacterium breve CCFM1025 can improve autonomous behaviors and exploration behaviors caused by the autism in an unfamiliar environment, alleviate social barriers caused by the autism, significantly improve stereotyped behaviors caused by the autism, and improve the cognitive ability of new objects, improve hyperactivity symptoms, and effectively adsorb the PCBs.

Description

technical field [0001] The invention belongs to the technical field of functional microorganisms, and specifically relates to the application of CCFM1025 in the preparation of food or medicine for relieving autism and adsorbing PCBs. Background technique [0002] Autism (Autism), also known as autism, has been recognized as a generalized neurodevelopmental disorder that frequently occurs in infants and young children, mainly manifested in social interaction impairment, communication (verbal and non-verbal) function impairment, and repetitive stereotyped behaviors. , often accompanied by a variety of clinical symptoms such as mental retardation, epilepsy or hyperactivity, usually before the age of 3. According to the latest data released by the US Centers for Disease Control and Prevention (CDC), the prevalence of ASD in 2018 was 1:59, a 15% increase from 1:68 in 2016, and the prevalence rate of men was 4 to 5 times that of women. . [0003] ASD is a highly heterogeneous ne...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/745A23C9/123A23L11/00A23L19/00A23L33/135A61P25/00A61P25/14
CPCA61K35/745A61P25/00A61P25/14A23L33/135A23C9/1234A23L19/00A23V2002/00A23L11/50A23V2400/519A23V2200/322
Inventor 王刚陈卫孔庆敏赵建新张灏
Owner JIANGNAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com